Studieoverzicht
Study name: Prediction
| Histology | NSCLC, all subtypes | ||
|---|---|---|---|
| Tumor stage | Stage I - III | ||
| Host / recruiting site 1 | LUMC | Enrollment | Closed |
| Therapy line | First line (1L) | ||
| Design |
Prospectief observationeel multicenter studie |
||
| Intervention | NVT |
||
| Key outcome parameters | Rol van het microbioom mbt voorspellen respons en toxiciteit van Durvalumab |
||
| Key inclusion criteria | Stadium IIIA-C NSCLC die Durvalumab gaan krijgen |
||
| Key exclusion criteria | Eerder PD-L1 inhibtor, auto-immuunziekten, steroiden (equivalent >10mg prednisone) |
||
| Contact information | Log in voor de contactinformatie | ||